drugset / Trial / NCT03474770

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

NCT03474770

Phase 1/2 Active not recruiting 16 enrolled Supernus Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.

Timeline

Start
2018-04-10
Primary completion
2026-12-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Huperzine A Traditional medicine (herbal / TCM) 1.75 mg

Indications